article thumbnail

STAT+: Juul spent big to court Black leaders to promote its e-cigarettes, new documents show

STAT

Documents released this week shed new light on an aggressive strategy from vape maker Juul to court Black leaders, including the Rev. Al Sharpton, to publicly support its e-cigarettes. It’s not clear how much the company ultimately spent on the partnerships. Continue to STAT+ to read the full story…

article thumbnail

Juul’s internal playbook opens a rare window into influence in Washington

STAT

WASHINGTON — A new trove of internal emails and other documents from the e-cigarette maker Juul reveals the company’s extensive behind-the-scenes efforts to promote its interests in Washington — a rare insight into the otherwise opaque methods corporations use to influence the government.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

NICE recommends first licenced treatment for AL amyloidosis

European Pharmaceutical Review

NICE’s positive decision, which is detailed in the final appraisal document , follows an appeal against NICE’s original guidance from November 2022. The document highlighted that daratumumab in combination “increases the time until systemic AL amyloidosis gets worse compared with bortezomib plus cyclophosphamide and dexamethasone.”

article thumbnail

FDA Proposes Select Updates to the Breakthrough Devices Program Designed to Reduce Health Care Disparities

The FDA Law Blog

Cato — On October 21, 2022, FDA published a draft guidance document titled Select Updates for the Breakthrough Devices Program Guidance: Reducing Disparities in Health and Health Care. This draft guidance proposes updates to FDA’s Breakthrough Devices Program, which is outlined in a separate December 2018 guidance document.

FDA 59
article thumbnail

The GoCART Coalition: Guidance for pharmacists

Hospital Pharmacy Europe

1,2 CAR T-cell products, such as tisagenlecleucel and axicabtagene ciloleucel, have been available on the European market for clinical use since 2018 3-5 and are used to treat patients who have not responded to other first-line therapies. 11 Many documents and checklists detail every stage of the pathway in preparing CAR T.

article thumbnail

EMA sets out proposals to reform EU’s clinical trials framework

pharmaphorum

The broad strokes of the proposals are laid out in a document entitled Accelerating Clinical Trials in the EU (ACT EU) that lists priority actions that will be taken, including measures to allow greater use of innovative clinical trial designs.

article thumbnail

510(k) Modernization 2023

The FDA Law Blog

Lenz, Principal Medical Device Regulation Expert — On September 6, 2023, FDA announced its latest efforts to modernize the 510(k) process, outlining FDA’s latest improvements to strengthen the 510(k) Program and announcing release of three draft guidance documents.